Core Viewpoint - 科济药业-B (02171) has seen a nearly 4% increase in stock price, currently trading at 16.27 HKD, with a transaction volume of 4.9417 million HKD. The company announced a clinical collaboration with Dispatch Bio to initiate a Phase I clinical trial in China by 2026, focusing on the application of the combined therapy DISP-11 in solid tumor patients [1]. Group 1 - The collaboration with Dispatch Bio involves the use of the Flare platform to develop a universal treatment for solid tumors [1]. - The combined therapy consists of Dispatch's investigational therapy, including the novel tumor-specific virus DV-10, and 科济药业's targeted BCMA autologous CAR-T cell product,赛恺泽 (泽沃基奥仑赛注射液) [1]. - 赛恺泽 has already received approval from the National Medical Products Administration (NMPA) in China for the treatment of multiple myeloma [1].

Core Viewpoint - Kintor Pharmaceutical Co., Ltd. (02171) has seen a nearly 4% increase in stock price following the announcement of a clinical collaboration with Dispatch Bio to initiate a Phase I clinical trial in China by 2026 for a combination therapy targeting solid tumors [1] Group 1: Company Developments - Kintor Pharmaceutical has partnered with Dispatch Bio, a biotechnology company that utilizes its proprietary Flare platform to develop treatments for solid tumors [1] - The planned Phase I clinical trial will evaluate the application of the combination therapy DISP-11 in patients with solid tumors [1] Group 2: Product Information - The combination therapy consists of Dispatch's investigational therapy, including the novel tumor-specific virus DV-10, and Kintor's targeted BCMA autologous CAR-T cell product, SaiKezai (Zevorikioran injection) [1] - SaiKezai has already received approval from the National Medical Products Administration (NMPA) in China for the treatment of multiple myeloma [1]

Core Viewpoint - The announcement highlights a clinical collaboration between Kogei Pharmaceuticals and Dispatch Bio to initiate a Phase I clinical trial in China by 2026, focusing on the application of the combined therapy DISP-11 in patients with solid tumors [1] Group 1: Clinical Trial Details - The Phase I clinical trial will evaluate the combined therapy DISP-11, which includes Dispatch's investigational therapy developed on the Flare platform, featuring a novel tumor-specific virus DV-10 [1] - The combined therapy will also utilize Kogei Pharmaceuticals' targeted BCMA autologous CAR-T cell product, Zekai (CT053), which has already received approval from the National Medical Products Administration (NMPA) in China for the treatment of multiple myeloma [1]

Core Insights - Kogei Pharmaceuticals has submitted two new drug clinical trial applications for its universal BCMA CAR-T product CT0596 to the National Medical Products Administration, targeting relapsed/refractory multiple myeloma and primary plasma cell leukemia [1][17][22] - The development of universal CAR-T therapies is seen as a significant advancement in the treatment of multiple myeloma, which remains incurable despite recent therapeutic advancements [2][19] - CT0596 is developed on the THANK-u Plus platform, which enhances the product's durability and safety by gene editing to reduce the risk of graft-versus-host disease and immune rejection [4][21] Group 1: Clinical Development - CT0596 has shown promising preliminary efficacy and safety in early human studies, with 6 out of 8 patients achieving partial response or better, and no severe adverse events reported [4][21] - The submission of clinical trial applications marks the entry of CT0596 into the registration clinical development phase, potentially providing new treatment options for patients with R/R MM and pPCL [5][22] - Kogei plans to explore CT0596's application in other plasma cell tumors and plasma cell-driven autoimmune diseases [5][22] Group 2: Technological Advancements - The THANK-u Plus platform allows for immediate use and mass production of CAR-T cells, significantly reducing treatment costs compared to autologous CAR-T therapies [3][20] - Kogei has developed a robust pipeline of universal CAR-T products targeting various malignancies, including blood cancers and solid tumors, leveraging the advantages of the THANK-u Plus platform [6][23] Group 3: Market Position and Future Directions - Kogei's self-developed CAR-T product, Sazekai (Zewokaiolun), has been approved for use in relapsed or refractory multiple myeloma, with significant market penetration across over 20 provinces in China [29] - The company is actively pursuing partnerships to enhance the development and commercialization of its universal CAR-T products in mainland China [28][29] - The competitive landscape for CAR-T therapies is intensifying, with multiple companies exploring dual-target strategies and innovative delivery methods to improve patient outcomes [14][30]

Core Insights - Kintor Pharmaceutical (02171.HK) announced clinical data for its universal BCMA CAR-T product CT0596 and universal CD19/CD20 CAR-T product CT1190B, both showing promising safety and efficacy signals for treating relapsed/refractory multiple myeloma (R/R MM) and non-Hodgkin lymphoma (R/R NHL) respectively [1][2] Group 1: Product Development - CT0596 is a universal CAR-T cell therapy targeting BCMA, currently undergoing investigator-initiated clinical trials for R/R MM and plasma cell leukemia (PCL), with plans to submit an IND application in the second half of 2025 [1] - CT1190B targets CD19/CD20 and is involved in clinical trials for treating relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL) and severe refractory systemic lupus erythematosus (SLE) or refractory/progressive systemic sclerosis (SSc) [2] Group 2: Company Overview - Kintor Pharmaceutical is a biopharmaceutical company focused on developing innovative CAR-T cell therapies to address unmet clinical needs, including hematologic malignancies, solid tumors, and autoimmune diseases [2] - The company has established end-to-end capabilities in CAR-T cell research and development, from target discovery to commercial-scale production, positioning itself as a leading global player in CAR-T therapy [2] - Kintor currently has 10 CAR-T pipeline products, including 4 autologous CAR-T and 6 universal CAR-T, all of which are self-developed with global rights [2]

Core Viewpoint - Kintor Pharmaceutical Co., Ltd. (科济药业-B) shares rose over 9% following the announcement of positive results from a clinical trial for its CAR-T cell therapy targeting pancreatic cancer, which was presented at the ESMO annual meeting [1] Group 1: Clinical Trial Results - Kintor's CAR-T cell product, CT053 (赛恺泽), is undergoing an Ib phase registration clinical trial in China for adjuvant therapy in pancreatic cancer [1] - This trial is the first global study exploring CAR-T cell therapy for adjuvant treatment in solid tumors [1] Group 2: Regulatory Developments - On September 20, the National Healthcare Security Administration (国家医保局) announced the completion of expert review for the first version of the commercial insurance innovative drug catalog [1] - Kintor's CT053, along with four other CAR-T drugs, passed the expert review and is expected to be included in this year's basic medical insurance catalog and commercial insurance innovative drug catalog [1]

Core Viewpoint - Kintor Pharmaceutical Co., Ltd. (02171) experienced a significant stock increase of over 9%, reaching HKD 17.66 with a trading volume of HKD 11.95 million, following the announcement of positive clinical trial results for its CAR-T cell therapy targeting pancreatic cancer [1] Group 1: Clinical Trial Results - Kintor announced that the results of its Phase Ib registration clinical trial for the CAR-T cell product CT053 (Zevoracel) targeting BCMA in the treatment of pancreatic cancer have been presented at the 2025 European Society for Medical Oncology (ESMO) annual meeting [1] - This trial is noted as the first global study exploring CAR-T cell therapy for adjuvant treatment in solid tumors, marking a significant milestone in the field [1] Group 2: Insurance and Reimbursement Developments - On September 20, the National Healthcare Security Administration announced the completion of expert review work for the first version of the commercial insurance innovative drug catalog [1] - Kintor's Zevoracel, along with four other CAR-T drugs, successfully passed the expert review and is expected to be included in this year's basic medical insurance catalog and commercial insurance innovative drug catalog [1]

Core Insights - The introduction of a dual-track payment system for innovative drugs in China marks a significant shift in the healthcare landscape, allowing high-priced CAR-T therapies to enter both the basic medical insurance and commercial insurance innovation drug directories [1][4][5] Group 1: Policy Changes - The National Healthcare Security Administration (NHSA) announced that five CAR-T drugs have passed expert review and are expected to be included in the basic medical insurance and commercial insurance innovation drug directories [1][5] - The establishment of the commercial insurance innovation drug directory provides a separate pathway for high-value, innovative drugs that exceed the basic insurance coverage [1][5] Group 2: Market Dynamics - The dual-track system aims to address the challenges of high-priced drug payments, as traditional basic medical insurance has struggled to accommodate the rising costs of innovative therapies [4][5] - The commercial insurance directory is designed to complement the basic medical insurance directory, allowing companies to choose to apply for either or both directories [5][8] Group 3: CAR-T Drug Insights - The five CAR-T products that passed the review include therapies from companies such as Fosun Kite, WuXi AppTec, and others, with each treatment priced around 1 million yuan per dose [7][8] - The inclusion of CAR-T therapies in the commercial insurance directory is expected to alleviate the financial burden on patients, as seen with Fosun Kite's product, which has been covered by various commercial health insurance plans [7][8] Group 4: Future Implications - The commercial insurance innovation drug directory is anticipated to serve as a transitional phase for innovative drugs before they potentially enter the basic medical insurance directory, based on real-world data and market validation [8] - The establishment of this directory is reshaping the Chinese innovative drug market, making previously inaccessible high-priced therapies more available to a broader patient population [8]

Core Viewpoint - The long-term follow-up results of the CAR-T cell therapy product Zevor-cel for treating relapsed/refractory multiple myeloma have been presented at the 22nd International Myeloma Society (IMS) Annual Meeting [1] Group 1: Product Information - Zevor-cel (CT053) is a fully human anti-BCMA CAR-T cell product designed for the treatment of multiple myeloma (MM) [1] - The National Medical Products Administration approved Zevor-cel for marketing on February 23, 2024, for adult patients with relapsed or refractory multiple myeloma who have progressed after at least three lines of treatment [1] - The product has received the Regenerative Medicine Advanced Therapy (RMAT) designation and orphan drug status from the FDA in 2019 [1] Group 2: Clinical Trial Updates - The updated results of the Phase I clinical trial were presented on September 17, 2025, at the IMS Annual Meeting, focusing on long-term follow-up of patients treated with Zevor-cel [1] - The presentation was titled "Long term Follow-up of Zevor-cel in Patients with Relapsed/Refractory Multiple Myeloma" [1]

Core Insights - In the first half of 2025, the company achieved a total revenue of 21.675 billion yuan, representing a year-on-year growth of 3.39%, and a net profit attributable to shareholders of 1.815 billion yuan, up 7.01% year-on-year [1] - The company plans to distribute a dividend of 614 million yuan, which accounts for 33.83% of the net profit attributable to shareholders for the first half of 2025 [1] Group 1: Pharmaceutical Business Performance - The core subsidiary, China Medical East, maintained good growth with a revenue of 7.317 billion yuan, a year-on-year increase of 9.24%, and a net profit of 1.580 billion yuan, up 14.09% year-on-year [1] - The innovative product business has seen significant growth, achieving sales and agency service revenue of 1.084 billion yuan, with a year-on-year increase of 59% [1] Group 2: Commercialization and Product Development - The company has a strong commercialization capability, with its exclusive partner, Kexi Pharmaceutical, seeing positive clinical feedback for its CAR-T product, which has expanded rapidly across over 20 provinces and cities [2] - The company has placed 111 valid orders with Kexi Pharmaceutical and has over 100 insurance and welfare insurance projects included in the reimbursement scope, indicating potential for continued high growth [2] Group 3: Research and Development - In the first half of 2025, the company invested 1.484 billion yuan in R&D, a year-on-year increase of 33.75%, with direct R&D expenses of 1.174 billion yuan, up 54.21% year-on-year, representing 15.97% of the pharmaceutical industrial revenue [3] - The company is advancing over 80 innovative drug pipelines, with a strategic focus on oncology, endocrinology, and autoimmune diseases, having launched global first-in-class drugs in these areas [3] - The company is conducting Phase II clinical trials for its GLP-1R/GIPR dual-target long-acting peptide HDM1005, with the weight management indication expected to enter Phase III trials in Q4 2025 [3] Group 4: Other Business Segments - The pharmaceutical commercial segment achieved a revenue of 13.947 billion yuan, a year-on-year growth of 2.91%, and a net profit of 226 million yuan, up 3.67% year-on-year [4] - The industrial microbiology sector is focusing on enhancing international competitiveness through four core business areas: xRNA raw materials, specialty APIs and intermediates, health products, and animal health [4] - The aesthetic medicine segment has achieved full coverage in the non-surgical aesthetic injection products and energy source devices market, with 26 out of 40 international products already launched and sold domestically and internationally [4]